Clinical and Biostatistics Core

临床和生物统计学核心

基本信息

  • 批准号:
    10260847
  • 负责人:
  • 金额:
    $ 102.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-01 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract – Clinical and Biostatistics Core The Clinical and Biostatistics Core (CBC) is a central component of the Evaluating Modes of Influenza Transmission (EMIT-2) program. The overall objective of this core is to perform a series of randomized clinical studies of influenza transmission to comprehensively evaluate viral, host, physical, and environmental factors that facilitate efficient human-to-human influenza transmission. In these studies, healthy participants who have no or very low levels of hemagglutination inhibiting antibodies to the current year’s vaccine strains will spend up to four days in contact with participants naturally infected with influenza virus and recruited by Research Project 1 (RP1). Each study in the series will employ an environmental intervention and a personal protection intervention designed by Research Project 2 (RP2). The core will provide the platform for collection of clinical and environmental samples by each of the two projects and the Advanced Bioaerosol Technology Core (ABTC). The clinical research facility for this project, Pharmaron Baltimore, has a long history of collaboration with the University of Maryland Center for Vaccine Development and is a site for the NIAID CIVIC program. The goals of this core will be achieved through the following specific aims: (1) Provide regulatory and safety infrastructure for a randomized controlled trial of influenza transmission; (2) Screen for healthy adult volunteers (Recipients), willing to temporarily reside on an inpatient containment unit approximately 2 weeks during the influenza season, and index cases with acute influenza infection (Donors); and (3) Expose un-infected eligible volunteers to influenza-infected index case patients. An independent Data and Safety Monitoring Board will be assembled to provide safety oversight over the conduct of the transmission studies. Ultimate oversight of the CBC’s activity will be the responsibility of the Core Leader (Dr. Chen) and Co-Investigator (Dr. Ortiz) and will include close coordination with the Projects and Cores of this U19.
项目摘要/摘要-临床和生物统计学核心

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wilbur H. Chen其他文献

A site assessment tool for inpatient controlled human infection models for enteric disease pathogens
肠道疾病病原体住院控制人体感染模型的现场评估工具
  • DOI:
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    2.7
  • 作者:
    C. Porter;Kate Detizio;Nicole Maier;K. J. Testa;K. Talaat;Wilbur H. Chen;Caroline E. Lyon;R. Gutierrez;R. Frenck;S. D. Isidean;R. Kaminski;A. Alcala;K. Hanevik;F. Sawe;B. Kirkpatrick;A. Louis Bourgeois
  • 通讯作者:
    A. Louis Bourgeois
Evidence for CVD 103-HgR as an effective single-dose oral cholera vaccine.
CVD 103-HgR 作为有效的单剂量口服霍乱疫苗的证据。
  • DOI:
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    3.1
  • 作者:
    Sarah S. Jackson;Wilbur H. Chen
  • 通讯作者:
    Wilbur H. Chen
Antibody against Microbial Neuraminidases Recognizes Human Sialidase 3 (NEU3): the Neuraminidase/Sialidase Superfamily Revisited
微生物神经氨酸酶抗体可识别人唾液酸酶 3 (NEU3):重新审视神经氨酸酶/唾液酸酶超家族
  • DOI:
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    C. Feng;Jihong Li;G. Snyder;Wei Huang;S. Goldblum;Wilbur H. Chen;Lai;B. McClane;A. Cross
  • 通讯作者:
    A. Cross
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial
在马里针对 9 个月和 15 个月大儿童常规接种儿童疫苗时,同时接种针对 A、C、W、Y 和 X 群的五价脑膜炎球菌结合疫苗的安全性和免疫原性:一项单中心、双盲、随机、对照、3 期非劣效性试验
  • DOI:
    10.1016/s0140-6736(25)00046-7
  • 发表时间:
    2025-03-29
  • 期刊:
  • 影响因子:
    88.500
  • 作者:
    Fatoumata Diallo;Fadima C Haidara;Milagritos D Tapia;Clara P Dominguez Islas;Mark R Alderson;William P Hausdorff;Lionel Martellet;Nancy Hosken;Dhananjay Kapse;Prasad S Kulkarni;Kelly Townsend-Payne;Francesca Vanni;Christine M Posavad;Samba O Sow;Karen L Kotloff;Wilbur H Chen;Fatoumata Diallo;Fadima C. Haidara;Milagritos D. Tapia;Souleymane Diakité;Wilbur H. Chen
  • 通讯作者:
    Wilbur H. Chen
Human antibody responses following vaccinia immunization using protein microarrays and correlation with cell-mediated and antibody dependent cellular cytotoxicity responses.
使用蛋白质微阵列进行痘苗免疫后的人类抗体反应以及与细胞介导和抗体依赖性细胞毒性反应的相关性。
  • DOI:
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    S. Frey;Jack T. Stapleton;Z. Ballas;Wendy L Rasmussen;T. Kaufman;Tammy P Blevins;Travis L. Jensen;D. H. Davies;Magdalena Tary;Paul Chaplin;H. Hill;Johannes B. Goll;R. Belshe;Anna Wald;Christine Johnston;Lisa A. Jackson;Patricia L. Winokur;W. Keitel;Hana M El Sahly;R. Atmar;Shital M. Patel;S. El;Wilbur H. Chen;Srilatha Edupuganti;N. Rouphael;Mark J. Mulligan;Kathryn M. Edwards;C. B. Creech
  • 通讯作者:
    C. B. Creech

Wilbur H. Chen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Wilbur H. Chen', 18)}}的其他基金

Clinical and Biostatistics Core
临床和生物统计学核心
  • 批准号:
    10471981
  • 财政年份:
    2021
  • 资助金额:
    $ 102.2万
  • 项目类别:
Clinical and Biostatistics Core
临床和生物统计学核心
  • 批准号:
    10645159
  • 财政年份:
    2021
  • 资助金额:
    $ 102.2万
  • 项目类别:
Bacteriophage-based approach for managing Shigella infections
基于噬菌体的志贺氏菌感染管理方法
  • 批准号:
    10158437
  • 财政年份:
    2020
  • 资助金额:
    $ 102.2万
  • 项目类别:
Bacteriophage-based approach for managing Shigella infections
基于噬菌体的志贺氏菌感染管理方法
  • 批准号:
    10397590
  • 财政年份:
    2020
  • 资助金额:
    $ 102.2万
  • 项目类别:
Bacteriophage-based approach for managing Shigella infections
基于噬菌体的志贺氏菌感染管理方法
  • 批准号:
    10624218
  • 财政年份:
    2020
  • 资助金额:
    $ 102.2万
  • 项目类别:
CLINICAL TRIAL: PHASE I/II STUDY OF A BOOSTER DOSE OF A/H5N1/INDONESIA/05/05 (CL
临床试验:A/H5N1 加强剂量的 I/II 期研究/INDONESIA/05/05 (CL
  • 批准号:
    7951184
  • 财政年份:
    2009
  • 资助金额:
    $ 102.2万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 102.2万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 102.2万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 102.2万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 102.2万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 102.2万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 102.2万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 102.2万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 102.2万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 102.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 102.2万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了